Carboplatin in clinical stage I seminoma: A valuable option for patient management

Journal of Clinical Oncology

Volumn 29, Issue 31, 2011, Pages 4210-4211

  Stenning, Sally ^a   Oliver, Tim ^b   Mead, Ben ^c   Gabe, Rhian ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN;

CANCER ADJUVANT THERAPY; CANCER STAGING; DATA ANALYSIS; DRUG CHOICE; DRUG EFFICACY; FOLLOW UP; HUMAN; LETTER; MEDICAL DECISION MAKING; PRIORITY JOURNAL; SEMINOMA;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; HUMANS; MALE; ORCHIECTOMY; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 80755180787     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.2434     Document Type: Letter

References (3)

1. Bosl GJ, Patil S: Carboplatin in clinical stage I seminoma: Too much and too little at the same time. J Clin Oncol 29:949-952, 2011
2. Oliver RTD, Mead GM, Rustin GJS, et al.: Randomized trial of carboplatin versus radiotherapy for stage I seminoma: Mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30892 study (ISRCTN27163214). J Clin Oncol 29:957-962, 2011
3. Mead GM, Fossa SD, Oliver RTD, et al.: Randomized trials in 2466 patients with stageIseminoma:Patterns of relapseandfollow-up.JNatlCancerInst103:241-249, 2011